Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on ...

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- On December 13, 2024, the Board of Directors of AGF Management Limited declared a ...

Acoramidis is a selective small molecule, orally administered near-complete transthyretin stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive ...

This approval is based on positive results from the attribute-cm phase 3 study, which enrolled 632 participants with symptomatic ATTR-CM. The results from the study demonstrated significant ...

The findings could potentially enable patients to be identified and treated before symptoms of ATTR-CM emerge.

Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations ...

The new understanding of molecular events that drive the various forms of amyloidosis has generated treatment strategies that ...

A ketone body, a molecule derived from the metabolism of acids to obtain energy when glucose is not available, could become ...

The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...

Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...

UK: A recent retrospective cohort study has highlighted the critical role of kidney function in patients diagnosed with ...